<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708889</url>
  </required_header>
  <id_info>
    <org_study_id>AI452-019</org_study_id>
    <nct_id>NCT01708889</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction</brief_title>
  <acronym>PK</acronym>
  <official_title>An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of renal impairment on pharmacokinetics
      (PK) of BMS-914143.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary purpose: Protocol designed to evaluate the effect of renal impairment on
      pharmacokinetics of BMS-914143
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time 0 extrapolated to infinity [AUC(INF)] of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration [AUC(0-T)] of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CLT/F) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) using serum levels of Lambda</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-HALF) using serum levels of Lambda</measure>
    <time_frame>18 time points up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessed by serum levels of anti-Lambda antibodies</measure>
    <time_frame>5 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)</measure>
    <time_frame>Up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs) Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)</measure>
    <time_frame>Approximately up to Day 73</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Chronic Hepatitis B Virus Infection</condition>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: BMS-914143 (eGFR &lt; 15 mL/min/1.73 m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR &lt; 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-914143 (Peginterferon Lambda-1a)</intervention_name>
    <arm_group_label>Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)</arm_group_label>
    <arm_group_label>Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)</arm_group_label>
    <arm_group_label>Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)</arm_group_label>
    <arm_group_label>Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)</arm_group_label>
    <arm_group_label>Group 5: BMS-914143 (eGFR &lt; 15 mL/min/1.73 m2)</arm_group_label>
    <other_name>Lambda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal renal function or mild, moderate, severe or end-stage renal dysfunction

        Exclusion Criteria:

          -  History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal,
             hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6
             months of Lambda administration

          -  History of chronic liver disease including cirrhosis, hepatitis B virus (HBV),
             hepatitis C virus (HCV), primary biliary cirrhosis, etc

          -  History of central nervous system or neuro-psychiatric disease. Subjects with severe
             depression and/or other uncontrolled psychiatric conditions should not be enrolled in
             this study

          -  History of of suicide attempt within the 5 years preceding BMS-914143 administration

          -  Inability to tolerate subcutaneous injections

          -  Donation of &gt;400 mL of blood within 8 weeks or plasma within 4 weeks of planned dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Of Miami Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center For Clinical Research - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2012</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

